JD Supra2d
To Be Or Not To Be: Self-Revocation of Seminal European Patents Creates New Uncertainty In CRISPR IP Space
The newest one is the self-revocation of two seminal CRISPR patents in Europe by the team led by two Nobel Laureates ...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Business Insider1d
Intellia Therapeutics (NTLA) Gets a Buy from Truist Financial
The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered ...
MIT Technology Review6d
The US is about to make a sharp turn on climate policy
The US, which is currently the world’s second-largest greenhouse-gas emitter and has added more climate pollution to the atmosphere than any other nation, is now very unlikely to hit Biden’s 2030 goal ...
Intellia Therapeutics: Strong Financials and Program Advancements Justify Buy Rating
Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on NTLA stock, giving a Buy rating today. Whitney Ijem has given ...
Cautious Optimism: Intellia Therapeutics Hold Rating Amidst Promising Trial Developments and Financial Stability
JMP Securities analyst Silvan Tuerkcan has maintained their neutral stance on NTLA stock, giving a Hold rating on October 25. Silvan ...
Business Insider5d
Intellia Therapeutics: Promising Gene-Editing Advancements and Strong Financial Position Support Buy Rating
The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered ...
Wells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), ...
Business Insider5d
Intellia Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered ...
Business Insider4d
Evercore ISI Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered ...
Business Insider5d
Intellia Therapeutics’ Strategic Advancements and Promising NTLA-2001 Progress Boost Buy Rating
The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered ...
Page Six6d
Jennifer Lopez details holiday plans after ‘intense year’ and Ben Affleck divorce
It’s onward and upward for Jennifer Lopez, who says she’s excited about the upcoming holiday season after filing for divorce from Ben Affleck in August. “It was a pretty intense year for me ...